These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9117450)

  • 1. A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication.
    Cruikshank WW; Doctrow SR; Falvo MS; Huffman K; Maciaszek J; Viglianti G; Raina J; Kornfeld H; Malfroy B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):193-203. PubMed ID: 9117450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
    Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
    J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo.
    Re MC; Furlini G; Vignoli M; Ramazzotti E; Roderigo G; De Rosa V; Zauli G; Lolli S; Capitani S; La Placa M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):408-16. PubMed ID: 7583436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cell Internalizing Antibody Targeting Capsid Protein (p24) Inhibits the Replication of HIV-1 in T Cells Lines and PBMCs: A Proof of Concept Study.
    Ali SA; Teow SY; Omar TC; Khoo AS; Choon TS; Yusoff NM
    PLoS One; 2016; 11(1):e0145986. PubMed ID: 26741963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies.
    Mhashilkar AM; LaVecchio J; Eberhardt B; Porter-Brooks J; Boisot S; Dove JH; Pumphrey C; Li X; Weissmahr RN; Ring DB; Ramstedt U; Marasco WA
    Hum Gene Ther; 1999 Jun; 10(9):1453-67. PubMed ID: 10395371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients.
    Re MC; Furlini G; Vignoli M; Ramazzotti E; Zauli G; La Placa M
    Clin Diagn Lab Immunol; 1996 Mar; 3(2):230-2. PubMed ID: 8991642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture.
    Steinaa L; Sørensen AM; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):263-71. PubMed ID: 7832634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat.
    Poznansky MC; Foxall R; Mhashilkar A; Coker R; Jones S; Ramstedt U; Marasco W
    Hum Gene Ther; 1998 Mar; 9(4):487-96. PubMed ID: 9525310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of HIV-1 Tat traffic and function by transduction-competent single chain antibodies.
    Theisen DM; Pongratz C; Wiegmann K; Rivero F; Krut O; Krönke M
    Vaccine; 2006 Apr; 24(16):3127-36. PubMed ID: 16497417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals.
    Belliard G; Romieu A; Zagury JF; Dali H; Chaloin O; Le Grand R; Loret E; Briand JP; Roques B; Desgranges C; Muller S
    Vaccine; 2003 Jul; 21(23):3186-99. PubMed ID: 12804847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
    Daelemans D; Schols D; Witvrouw M; Pannecouque C; Hatse S; van Dooren S; Hamy F; Klimkait T; de Clercq E; VanDamme AM
    Mol Pharmacol; 2000 Jan; 57(1):116-24. PubMed ID: 10617686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR.
    Tosi G; Meazza R; De Lerma Barbaro A; D'Agostino A; Mazza S; Corradin G; Albini A; Noonan DM; Ferrini S; Accolla RS
    Eur J Immunol; 2000 Apr; 30(4):1120-6. PubMed ID: 10760801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
    Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
    J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intercellular traffic of human immunodeficiency virus type 1 transactivator protein defined by monoclonal antibodies.
    Demirhan I; Chandra A; Hasselmayer O; Chandra P
    FEBS Lett; 1999 Feb; 445(1):53-6. PubMed ID: 10069373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat.
    Poznansky MC; La Vecchio J; Silva-Arietta S; Porter-Brooks J; Brody K; Olszak IT; Adams GB; Ramstedt U; Marasco WA; Scadden DT
    Hum Gene Ther; 1999 Oct; 10(15):2505-14. PubMed ID: 10543615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load.
    Re MC; Gibellini D; Furlini G; Vignoli M; Vitone F; Bon I; La Placa M
    New Microbiol; 2001 Jul; 24(3):207-15. PubMed ID: 11497076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
    J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.